142 related articles for article (PubMed ID: 37378902)
1. Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients With Neuroendocrine Tumors and Carcinoid Syndrome.
Liu E; Hoffman KD; Murfin G; Eccard H
Pancreas; 2023 Jan; 52(1):e70-e74. PubMed ID: 37378902
[TBL] [Abstract][Full Text] [Related]
2. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
3. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
6. Management of Diarrhea in Patients With Carcinoid Syndrome.
Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
[TBL] [Abstract][Full Text] [Related]
7. Telotristat ethyl: a new option for the management of carcinoid syndrome.
Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW
Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224
[TBL] [Abstract][Full Text] [Related]
8. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
9. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
11. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
12. Carcinoid syndroma - diagnosis and management.
Kiňová S; Koreň M
Vnitr Lek; 2021; 67(5):310-314. PubMed ID: 35459398
[TBL] [Abstract][Full Text] [Related]
13. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin EM; Benson Iii AB
Oncology; 2019; 96(6):273-289. PubMed ID: 31018209
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
16. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
17. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
18. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]